Michael Marvin Levine, M.D., F.A.C.P.

Harrisburg, Pennsylvania

B.A. in Chemistry, Oberlin College, Oberlin, Ohio
Graduated with Honor

M.D., Baylor College of Medicine, Houston, Texas
Graduated with High Honor

Straight Medicine Internship, UCLA-CHS, Los Angeles, California

Residency, Internal Medicine, UCLA-CHS, Los Angeles, California

Nephrology Fellowship, UCSF, San Francisco, California

Nephrology Fellowship, UCLA-CHS, Los Angeles, California

Clinical Instructor in Medicine, UCLA Medical School

Clinical Associate Professor of Medicine, UCLA Medical School
Attending Staff, Cedars-Sinai Medical Center

Tower Nephrology

Diplomate, American Board of Internal Medicine, 1983

Board Certified in Subspecialty of Nephrology, 1985

A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease.

Study to evaluate the improved management of iPTH with paracalcitol- centered therapy vs. cinacalcet therapy with low-dose vitamin d in hemodialysis patients with secondary hyperparathyroidism.

A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor.

Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia.

A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin

Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis

A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®)

A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections.

Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease.

A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease

An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency

A randomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy.

Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events.

A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis.

An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease.

Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis.

Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis.

Phase 3 Cinacalcet open label to reach K/DOQI levels

Phase 3 trial in treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalce.

Phase 4 Prospective, Randomized, double-blind, double-dummy, forced- titration, multicenter, parallel group, one year treatment trial to compare MICARDIS (telmisartan) 80 mg versus COZAAR (losartan) 100mg, in hypertensive type 2 diabetic patients with overt nephropathy (AMADEO Study)

Phase 3 Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent When Two Different Vitamin D Regimens are used in Subjects with Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

Phase 4 to evaluate subject preference for Aranesp administered administered once monthly, ie every 4 weeks (Q4W) or procrit administered once weekly (QW).

Phase 3 Placebo-controlled, Double-blind, Extension Study to Assess the Long-term Safety of an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease.

Phase 4 Disease/Case Management of Patients Receiving ARANESP (darbepoetin alfa) to Treat the Anemia of Chronic Renal Insufficiency (CRI).

Phase 4, Multicenter Trial Using Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) and Iron Guided Algorithms to Treat Subjects with Anemia of Chronic Renal Insufficiency (CRI).

Phase 4 Multicenter Study Evaluating Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) in subjects with Anemia of Chronic Renal Insufficiency (CRI).

Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent on Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis.

Phase 3 A Multicenter, Open-label Extension Study to Assess the Long- term Safety and Efficacy if an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

Phase 2 Randomized, double-blind Study to Assess the Efficacy and safety of an Oral Calcimimetic Agent on secondary Hyperparathyroidism of End Stage Renal Disease treated with Hemodialysis.

Phase 2 Pharmacokinetic (PK) Analysis of Chronic Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) Therapy in Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis (HD).

Chronic Renal Insufficiency registry in a prospective, observational study designed to gather data on the use of various interventions delivered to patients with renal insufficiency, pre-ESRD.

Randomized Study Comparing the Efficiency of Once Weekly Versus 3 Times Weekly Administration of Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) to Subjects with End-Stage Renal Disease Receiving Hemodialysis.